Diabetes Mellitus, Type 2NCT06861062
Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Glycemic Control and Cardiovascular Disease Risk in Patients With Type 2 Diabetes
A study testing Vitamin D3 and yeast β-glucan in people with Diabetes Mellitus, Type 2, run by Huazhong University of Science and Technology at 5 sites in China.
Trial summary
This study is a randomized, double-blind, placebo-controlled trial involving 2,500 individuals aged 40-79 with type 2 diabetes (T2D). The trial includes a 2-year intervention period followed by a 3-year post-intervention follow-up. Read more about this study
- Who is it for?
- Ages 40 to 79 years
- Conditions the study is for
- Diabetes Mellitus, Type 2
- What is being tested?
- Vitamin D3 and yeast β-glucan
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 2,500 participants
- Where
- 5 sitesChina
- Study dates
- 8 Apr 2025to 31 Dec 2032
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 79 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Type 2 diabetes mellitus diagnosed by a physician based on the diagnostic criteria outlined in the Guideline for the Prevention and Treatment of Diabetes Mellitus in China (2024 Edition);
- Men or women aged 40-79 years;
- Convenient access to the study centers and permanent residence in the vicinity for the next five years;
- Voluntary participation and signed written informed consent.
Who cannot join
- History of clinical cardiovascular disease (including myocardial infarction, treatment or hospitalization for heart failure, stroke, and coronary revascularization) within the past 6 months;
- History of severe diabetic microvascular complications (diabetic nephropathy with an estimated glomerular filtration rate (eGFR) < 30 mL/(min·1.73m²), proliferative diabetic retinopathy, confirmed diabetic peripheral neuropathy with abnormal nerve conduction studies or small fiber neuropathy testing);
- History of cancer, excluding non-melanoma skin cancer or cancers with a favorable prognosis;
- History of kidney stones, hypercalcemia, or hyperparathyroidism;
- History of severe liver disease, severe kidney disease, severe gastrointestinal disease, severe infectious diseases, severe sarcoidosis or other granulomatous diseases, severe mental illness, or any other condition considered unsuitable for participation judged by the clinic team;
- Laboratory evaluation:
Show all 12Show fewer
- Blood calcium levels greater than or equal to the normal range for the clinical site's laboratory;
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels higher than 3 times the normal range for the clinical site's laboratory;
- eGFR < 30 mL/(min·1.73m²);
- Individuals currently taking vitamin D supplements (>400 IU/day), calcium supplements (>600 mg/day), yeast β-glucan supplements (>250 mg/day), or those with a history of allergy or intolerance to vitamin D or prebiotic products;
- Participation in other clinical trials within the past 3 months;
- Planning to become pregnant within the next five years, or currently pregnant or breastfeeding.
Trial locations and contacts
5 sites in 1 country. Contact the study team or a site near you to ask about taking part.
5 sites in 1 country
China5 sites, 5 recruiting
- Recruiting
Sichuan University
Chengdu, Sichuan
Jiayuan Li
- Recruiting
Guangxi Medical College
Nanning, Guangxi
Qiuli Chen
- Recruiting
Sinopharm Dongfeng General Hospital
Shiyan, Hubei
Kun Yang
- Recruiting
Kailuan General Hospital
Tangshan, Hebei
Shuohua Chen
- Recruiting
Huazhong University of Science and Technology
Wuhan, Hubei, 430000
Gang Liu, 86-15926238366, liugang026@hust.edu.cn
About this study
Official title: Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Glycemic Control and Cardiovascular Disease Risk in Patients With Type 2 Diabetes: A Randomized Double-Blind Controlled Trial
This study is a randomized, double-blind, placebo-controlled trial involving 2,500 individuals aged 40-79 with type 2 diabetes (T2D). The trial includes a 2-year intervention period followed by a 3-year post-intervention follow-up. The primary objective is to investigate (a) the effect of daily supplementation with vitamin D3 (1600 IU) or yeast β-glucan (600 mg) on glycemic control in patients with T2D and (b) whether daily supplementation with vitamin D3 (1600 IU) or yeast β-glucan (600 mg) reduces the predicted 10 year risk of atherosclerotic cardiovascular disease (ASCVD) in patients with T2D. The secondary objectives include evaluating the effects of vitamin D3 or yeast β-glucan supplementation on cardiometabolic risk factors, inflammatory markers, and liver and kidney function indicators, and assessing whether such supplementation reduces the risk of cardiovascular disease, microvascular complications and mortality over the 3-year post-intervention period.
Read the detailed description
The goal of this randomized, double-blind, placebo-controlled trial, with a 2×2 factorial design in individuals with type 2 diabetes (T2D), is to investigate (a) the effect of daily dietary supplementation with vitamin D3 (1600 IU) or yeast β-glucan (600 mg) on glycemic control in patients with T2D and (b) whether vitamin D3 (1600 IU) or yeast β-glucan (600 mg) supplementation reduces the predicted 10 year risk of atherosclerotic cardiovascular disease (ASCVD) in patients with T2D. Approximately 2,500 subjects aged 40-79 with T2D will be included in this study. Eligible participants will be randomly assigned to one of four groups: (1) daily vitamin D3 (1600 IU) and yeast β-glucan (600 mg); (2) daily vitamin D3 (1600 IU) and placebo for yeast β-glucan; (3) daily placebo for vitamin D3 and yeast β-glucan (600 mg); or (4) daily placebo for vitamin D3 and placebo for yeast β-glucan. At baseline, questionnaires will be administered to collect data on sociodemographic factors, lifestyle habits, health status, cognitive function, and medical conditions, et al. Participants will also undergo physical measurements, and blood, urine, and feces samples will be collected at study centers. The study includes a 2-year intervention period followed by a 3-year post-intervention follow-up. Participants in all groups will take four capsules daily for 2 years: two capsules containing either vitamin D or its placebo and two capsules containing either yeast β-glucan or its placebo. During the 2-year intervention period, questionnaires, physical measurements, and sample collection will be conducted at 6, 12, and 24 months. This trial will also evaluate the effects of supplementation on cardiometabolic risk factors, inflammatory markers, and liver and kidney function indicators, and assess whether it reduces the risk of cardiovascular disease, microvascular complications, and mortality over the 3-year post-intervention period, providing scientific evidence for the health effects of vitamin D or yeast β-glucan in the T2D population.
- Conditions
- Diabetes Mellitus, Type 2
- Being tested
- Vitamin D3, yeast β-glucan, Vitamin D placebo, yeast β-glucan placebo
- Keywords
- Vitamin D, yeast β-glucan, Diabetes Mellitus, Type 2, Cardiovascular Disease, glycemic control
- Medical subject headings
- Diabetes Mellitus, Type 2, Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Vitamin D3Drug
Also called cholecalciferol
Vitamin D3(cholecalciferol),1600 IU per day.
yeast β-glucanDietary supplement
yeast β-glucan, 600mg per day.
Vitamin D placeboDietary supplement
Vitamin D placebo
yeast β-glucan placeboDietary supplement
yeast β-glucan placebo
| Study group | Role | What they receive |
|---|---|---|
| Vitamin D + yeast β-glucan | Active comparator | Not described Receives: Drug: Vitamin D3; Dietary Supplement: yeast β-glucan |
| Vitamin D + yeast β-glucan placebo | Active comparator | Not described Receives: Drug: Vitamin D3; Dietary Supplement: yeast β-glucan placebo |
| yeast β-glucan +Vitamin D placebo | Active comparator | Not described Receives: Dietary Supplement: yeast β-glucan; Dietary Supplement: Vitamin D placebo |
| Vitamin D placebo + yeast β-glucan placebo | Placebo comparator | Not described Receives: Dietary Supplement: Vitamin D placebo; Dietary Supplement: yeast β-glucan placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Glycemic control
Change in HbA1c from baseline to the 24-month visit
Measured: 24 months
Cardiovascular disease risk
Change in 10-year ASCVD risk score from baseline to the 24-month visit, assessed using China-PAR score, with a score range of 0-100%, where a higher score means a higher ASCVD risk
Measured: 24 months
Secondary outcomes (29)
Blood 25(OH)D
Change in blood 25(OH)D concentrations from baseline to the 24-month visit
Measured: 24 months
Major cardiovascular events
Time to the first occurrence of any of the following: myocardial infarction, hospitalized or treated heart failure, stroke, revascularization of coronary arteries, or cardiovascular deaths
Measured: 60 months
Microvascular disease
Time to the first occurrence of any of the following: nephropathy, retinopathy, or neuropathy
Measured: 60 months
All-cause mortality
Deaths from any causes
Measured: 60 months
Change in fasting plasma glucose
Change in fasting plasma glucose from baseline to the 24-month visit. The value is reported in millimole per liter (mmol/L).
Measured: 24 months
Change in fasting C-peptide
Change in fasting C-peptide from baseline to the 24-month visit. The value is reported in nanogram per milliliter (ng/mL).
Measured: 24 months
Change in insulin
Change in insulin from baseline to the 24-month visit. The value is reported in microunit per milliliter (μU/mL).
Measured: 24 months
Change in HOMA-IR
Change in HOMA-IR from baseline to the 24-month visit. HOMA-IR = [Fasting Serum Insulin (μU/mL) × Fasting Plasma Glucose (mmol/L)] / 22.5. Lower values indicate better insulin sensitivity.
Measured: 24 months
Change in Lipid profile
Change in total cholesterol, triglycerides, LDL-cholesterol, and HDL-cholesterol from baseline to the 24-month visit. These values are reported in millimole per liter (mmol/L).
Measured: 24 months
Change in Liver function markers
Change in alanine aminotransferase (ALT), aspartate aminotransferase (AST), a nd gamma-glutamyl transferase (GGT) from baseline to the 24-month visit. These values are reported in units per liter (U/L).
Measured: 24 months
Change in serum creatinine
Change in serum creatinine from baseline to the 24-month visit. The value is reported in micromole per liter (μmol/L).
Measured: 24 months
Change in cystatin C
Change in cystatin C from baseline to the 24-month visit. The value is reported in milligram per liter (mg/L).
Measured: 24 months
Change in eGFR
Change in estimated glomerular filtration rate (eGFR) from baseline to the 24-month visit. The CKD-EPI (2009) method to estimate eGFR value. The value is reported in milliliter per minute per 1.73 square meters (mL/min/1.73 m²).
Measured: 24 months
Change in blood calcium
Change in blood calcium from baseline to the 24-month visit. The value is reported in millimole per liter (mmol/L).
Measured: 24 months
Change in body weight
Change in body weight from baseline to the 24-month visit. The value is reported in kilogram (kg).
Measured: 24 months
Change in BMI
Change in body mass index (BMI) from baseline to the 24-month visit. BMI = Body Weight (kg) / [Height (m)]^2. The value is reported in kilogram per square meter (kg/m^2).
Measured: 24 months
Change in waist circumference
Change in waist circumference from baseline to the 24-month visit. The value is reported in centimeter (cm).
Measured: 24 months
Change in waist-to-hip ratio
Change in waist-to-hip ratio from baseline to the 24-month visit. Waist-to-hip ratio = Waist Circumference (cm) / Hip Circumference (cm). Higher values indicate greater central adiposity.
Measured: 24 months
Change in blood pressure
Change in systolic and diastolic blood pressure from baseline to the 24-month visit. The values are reported in millimeters of mercury (mmHg).
Measured: 24 months
Change in grip strength
Change in grip strength from baseline to the 24-month visit, assessed using a handgrip dynamometer. The value is reported in kilogram (kg).
Measured: 24 months
Change in FRAIL scale
FRAIL scale comprises five domains: fatigue, resistance, ambulation, illnesses, and weight loss. Each item is scored as 0 or 1, yielding a total score ranging from 0 to 5, with higher scores indicating greater frailty. Based on the total score, patients were categorized as robust (0 points), pre-frail (1-2 points), or frail (3-5 points).
Measured: 24 months
Change in C-reactive protein
Change in C-reactive protein (CRP) from baseline to the 24-month visit. The value is reported in milligram per liter (mg/L).
Measured: 24 months
Change in procalcitonin
Change in procalcitonin from baseline to the 24-month visit. The value is reported in nanogram per milliliter (ng/mL).
Measured: 24 months
Change in interleukin-6
Change in interleukin-6 (IL-6) from baseline to the 24-month visit. The value is reported in picogram per milliliter (pg/mL).
Measured: 24 months
Bone mineral density
Change in bone mineral density from baseline to the 24-month visit, including but not limited to Speed of Sound (SOS), T-score, and Z-score. SOS is reported in meters per second （m/s). T-score and Z-score have no dimensional units.
Measured: 24 months
Change in baPWV
Change in brachial-Ankle Pulse Wave Velocity (baPWV) from baseline to the 24-month visit. The value is reported in centimeters per second (cm/s).
Measured: 24 months
Change in ABI
Change in Ankle-Brachial Index (ABI) from baseline to the 24-month visit. ABI=Systolic blood pressure of the ankle (mmHg) / Higher values of bilateral arm systolic pressure (mmHg).
Measured: 24 months
Change in LSM
Change in stiffness measurement (LSM) from baseline to the 24-month visit, assessed by transient elastography (FibroTouch). The value is reported in kilopascal (kPa).
Measured: 24 months
Change in UAP
Change in Ultrasound Attenuation Parameter (UAP) from baseline to the 24-month visit, assessed by transient elastography (FibroTouch). The value is reported in Decibel per Megahertz per Centimeter (dB/MHz/cm).
Measured: 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Mar 2025
- Study start8 Apr 2025
- Primary completion31 Dec 2030 (estimated)
- Study completion31 Dec 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetes Mellitus, Type 2Studies of the same condition, open and under way.
- More trials run by Huazhong University of Science and TechnologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 2,500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Huazhong University of Science and Technology
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, An Pan, Huazhong University of Science and Technology
- Investigators
- An Pan, PHD, Principal investigator, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06861062
- Sponsor's protocol ID
- VD, Yeast β-Glucan in Diabetes
- Status last verified
- Sep 2025
- First submitted
- 23 Feb 2025
- Last updated
- 2 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The individual participant data (IPD) sharing will need to be approved by the Institutional Review Board (IRB) and the study investigators with individual specific project request.
Study at a glance
From the registry record, last updated by the sponsor on 2 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Glycemic Control and Cardiovascular Disease Risk in Patients With Type 2 Diabetes: A Randomized Double-Blind Controlled Trial
- ClinicalTrials.gov ID
- NCT06861062
- Acronym / sponsor ID
- VD, Yeast β-Glucan in Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Keywords
- Vitamin D, yeast β-glucan, Diabetes Mellitus, Type 2, Cardiovascular Disease, glycemic control
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 2,500 participants (estimated)
- Lead sponsor
- Huazhong University of Science and TechnologyUniversity, hospital or other
- Study start
- 8 Apr 2025 (actual)
- Primary completion
- 31 Dec 2030 (estimated)
- Study completion
- 31 Dec 2032 (estimated)
- First posted
- 6 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a randomized, double-blind, placebo-controlled trial involving 2,500 individuals aged 40-79 with type 2 diabetes (T2D). The trial includes a 2-year intervention period followed by a 3-year post-intervention follow-up. The primary objective is to investigate (a) the effect of daily supplementation with vitamin D3 (1600 IU) or yeast β-glucan (600 mg) on glycemic control in patients with T2D and (b) whether daily supplementation with vitamin D3 (1600 IU) or yeast β-glucan (600 mg) reduces the predicted 10 year risk of atherosclerotic cardiovascular disease (ASCVD) in patients with T2D. The secondary objectives include evaluating the effects of vitamin D3 or yeast β-glucan supplementation on cardiometabolic risk factors, inflammatory markers, and liver and kidney function indicators, and assessing whether such supplementation reduces the risk of cardiovascular disease, microvascular complications and mortality over the 3-year post-intervention period.
Detailed description
The goal of this randomized, double-blind, placebo-controlled trial, with a 2×2 factorial design in individuals with type 2 diabetes (T2D), is to investigate (a) the effect of daily dietary supplementation with vitamin D3 (1600 IU) or yeast β-glucan (600 mg) on glycemic control in patients with T2D and (b) whether vitamin D3 (1600 IU) or yeast β-glucan (600 mg) supplementation reduces the predicted 10 year risk of atherosclerotic cardiovascular disease (ASCVD) in patients with T2D. Approximately 2,500 subjects aged 40-79 with T2D will be included in this study. Eligible participants will be randomly assigned to one of four groups: (1) daily vitamin D3 (1600 IU) and yeast β-glucan (600 mg); (2) daily vitamin D3 (1600 IU) and placebo for yeast β-glucan; (3) daily placebo for vitamin D3 and yeast β-glucan (600 mg); or (4) daily placebo for vitamin D3 and placebo for yeast β-glucan. At baseline, questionnaires will be administered to collect data on sociodemographic factors, lifestyle habits, health status, cognitive function, and medical conditions, et al. Participants will also undergo physical measurements, and blood, urine, and feces samples will be collected at study centers. The study includes a 2-year intervention period followed by a 3-year post-intervention follow-up. Participants in all groups will take four capsules daily for 2 years: two capsules containing either vitamin D or its placebo and two capsules containing either yeast β-glucan or its placebo. During the 2-year intervention period, questionnaires, physical measurements, and sample collection will be conducted at 6, 12, and 24 months. This trial will also evaluate the effects of supplementation on cardiometabolic risk factors, inflammatory markers, and liver and kidney function indicators, and assess whether it reduces the risk of cardiovascular disease, microvascular complications, and mortality over the 3-year post-intervention period, providing scientific evidence for the health effects of vitamin D or yeast β-glucan in the T2D population.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Vitamin D + yeast β-glucan | Active comparator | Drug: Vitamin D3, Dietary Supplement: yeast β-glucan |
| Vitamin D + yeast β-glucan placebo | Active comparator | Drug: Vitamin D3, Dietary Supplement: yeast β-glucan placebo |
| yeast β-glucan +Vitamin D placebo | Active comparator | Dietary Supplement: yeast β-glucan, Dietary Supplement: Vitamin D placebo |
| Vitamin D placebo + yeast β-glucan placebo | Placebo comparator | Dietary Supplement: Vitamin D placebo, Dietary Supplement: yeast β-glucan placebo |
Who may qualify
- Ages
- 40 to 79 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Type 2 diabetes mellitus diagnosed by a physician based on the diagnostic criteria outlined in the Guideline for the Prevention and Treatment of Diabetes Mellitus in China (2024 Edition);
- Men or women aged 40-79 years;
- Convenient access to the study centers and permanent residence in the vicinity for the next five years;
- Voluntary participation and signed written informed consent.
Key exclusion criteria (12 listed)
- History of clinical cardiovascular disease (including myocardial infarction, treatment or hospitalization for heart failure, stroke, and coronary revascularization) within the past 6 months;
- History of severe diabetic microvascular complications (diabetic nephropathy with an estimated glomerular filtration rate (eGFR) < 30 mL/(min·1.73m²), proliferative diabetic retinopathy, confirmed diabetic peripheral neuropathy with abnormal nerve conduction studies or small fiber neuropathy testing);
- History of cancer, excluding non-melanoma skin cancer or cancers with a favorable prognosis;
- History of kidney stones, hypercalcemia, or hyperparathyroidism;
- History of severe liver disease, severe kidney disease, severe gastrointestinal disease, severe infectious diseases, severe sarcoidosis or other granulomatous diseases, severe mental illness, or any other condition considered unsuitable for participation judged by the clinic team;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vitamin D3Also: cholecalciferolVitamin D3(cholecalciferol),1600 IU per day. | Drug | Vitamin D + yeast β-glucan, Vitamin D + yeast β-glucan placebo |
| yeast β-glucanyeast β-glucan, 600mg per day. | Dietary supplement | Vitamin D + yeast β-glucan, yeast β-glucan +Vitamin D placebo |
| Vitamin D placeboVitamin D placebo | Dietary supplement | Vitamin D placebo + yeast β-glucan placebo, yeast β-glucan +Vitamin D placebo |
| yeast β-glucan placeboyeast β-glucan placebo | Dietary supplement | Vitamin D + yeast β-glucan placebo, Vitamin D placebo + yeast β-glucan placebo |
Primary outcome
Glycemic control
Time frame: 24 months
Change in HbA1c from baseline to the 24-month visit
Cardiovascular disease risk
Time frame: 24 months
Change in 10-year ASCVD risk score from baseline to the 24-month visit, assessed using China-PAR score, with a score range of 0-100%, where a higher score means a higher ASCVD risk
29 secondary outcomes
Blood 25(OH)D
Time frame: 24 months
Major cardiovascular events
Time frame: 60 months
Microvascular disease
Time frame: 60 months
All-cause mortality
Time frame: 60 months
Change in fasting plasma glucose
Time frame: 24 months
Change in fasting C-peptide
Time frame: 24 months
Change in insulin
Time frame: 24 months
Change in HOMA-IR
Time frame: 24 months
Change in Lipid profile
Time frame: 24 months
Change in Liver function markers
Time frame: 24 months
Change in serum creatinine
Time frame: 24 months
Change in cystatin C
Time frame: 24 months
Change in eGFR
Time frame: 24 months
Change in blood calcium
Time frame: 24 months
Change in body weight
Time frame: 24 months
Change in BMI
Time frame: 24 months
Change in waist circumference
Time frame: 24 months
Change in waist-to-hip ratio
Time frame: 24 months
Change in blood pressure
Time frame: 24 months
Change in grip strength
Time frame: 24 months
Change in FRAIL scale
Time frame: 24 months
Change in C-reactive protein
Time frame: 24 months
Change in procalcitonin
Time frame: 24 months
Change in interleukin-6
Time frame: 24 months
Bone mineral density
Time frame: 24 months
Change in baPWV
Time frame: 24 months
Change in ABI
Time frame: 24 months
Change in LSM
Time frame: 24 months
Change in UAP
Time frame: 24 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Feb 2026.
- Individual participant dataSharing planned: No. The individual participant data (IPD) sharing will need to be approved by the Institutional Review Board (IRB) and the study investigators with individual specific project request.
Related trials for Diabetes Mellitus, Type 2
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
An Pan, PHD principal investigator
School of Public Health, Tongji Medical College, Huazhong University of Science and Technology
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Vitamin D3 and yeast β-glucan in people with Diabetes Mellitus, Type 2, run by Huazhong University of Science and Technology at 5 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Gang Liu, PHD (86-15926238366, liugang026@hust.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Glycemic control (time frame: 24 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Feb 2026.